As adeno-associated virus (AAV) remains the cornerstone of gene therapy, the question is no longer if it will scale globally, but how. Early developers face mounting pressure to design processes that anticipate commercial realities, while late-stage programs must navigate a complex landscape shaped by geopolitical shifts, international supply chain constraints, and evolving regulatory expectations. Success in this climate demands more than technical rigor—it requires strategic foresight. From securing raw materials and building resilient global supply networks to adopting platform approaches and advanced analytics, proactive planning is essential. For sponsors, embedding these considerations early ensures scalability and accelerates progression, while late-phase teams must align manufacturing strategies with global market dynamics to achieve sustainable commercial success.

Philip Wills (Chief Commercial Officer | Catalent)

Paul Herzich (Chief Technology Officer | Solid Biosciences)

Scott Jeffers (Chief Technology Officer | GenSight Biologics)

Bernd Schmidt (Chief Technical Officer | Sensorion)

What's next for AAV?